China’s biggest drug company launches billion-dollar Hong Kong IPO

China’s biggest drug company launches billion-dollar Hong Kong IPO

Singapore-based medical testing firm Mirxes joins Jiangsu Hengrui Pharmaceuticals in revitalised market’s listing surge.

Hengrui Pharma Seeks Up to $1.3 Billion in Hong Kong Listing

Jiangsu Hengrui Pharmaceuticals Co. has started taking investor orders for a Hong Kong listing that could raise as much as HK$9.9 billion ($1.3 billion), the latest significant deal to boost the financial hub’s share-sale recovery.

Singapore biotech firm Mirxes launches IPO in Hong Kong to raise HK$1 billion

Singapore biotech start-up Mirxes launched its initial public offering (IPO) in Hong Kong on Thursday (May 15) as it seeks to raise HK$1.09 billion (S$181 million) to further grow the business.

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

Jiangsu Hengrui, a 55-year-old drugmaker that has become one of China's leading forces in biotech, expects net proceeds of about 9.4 billion Hong Kong dollars ($1.2 billion) from its proposed float on the Hong Kong ...

Billion-dollar Hong Kong IPOs keep coming as China’s biggest drug company joins rush

Singapore-based medical testing firm Mirxes joins Jiangsu Hengrui Pharmaceuticals in revitalised market’s listing surge.